(P029) A Comparison of CT- and MRI-Defined Lumpectomy Cavity for Radiotherapy Planning of Breast Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

MRI substantially improves the visibility and accuracy of lumpectomy cavity definition as compared with CT. Although the LC and PTV volumes that are delineated from an individual MRI sequence are generally smaller as compared with those from CT, the volumes, shapes, and locations for the PTV-MRI, defined by the union of T1, T2, and STIR, were comparable with PTV-CT for most of the cases studied. It is feasible to use MRI to replace CT in RT simulations for breast-conserving RT.

Wei Huang, MD, PhD, Adam Currey, MD, Victor Chen, PhD, Frank Wilson, MD, Allen Li, PhD; Medical College of Wisconsin

PURPOSE: To compare lumpectomy (LC) and planning target volume (PTV) that is delineated using magnetic resonance imaging (MRI) and computed tomography (CT) and examine the possibility of replacing CT with MRI for radiotherapy (RT) planning for breast cancer.

MATERIALS AND METHODS: MRI and CT data were acquired for 14 patients with early-stage breast cancer who had undergone lumpectomy at their radiation treatment positions (prone) using a large-bore CT scanner (HighSpeed, GE) and a 3-T large-bore MRI scanner (Vero, Siemens) during RT simulation. All patients had dense breast tissues. The LCs were delineated manually on both CT (LC-CT) and MRI acquired with three sequences (T1, T2, and short TI inversion recovery [STIR]) (LC-T1, LC-T2, and LC-STIR, respectively) by a radiation oncologist and verified by another radiation oncologist. The PTV (PTV-MRI) was created by expanding a uniform 15-mm margin from the union of the LC-T1, LC-T2, and LC-STIR and was compared with those from CTs (PTV-CT). Differences were measured in terms of cavity visualization score (CVS), volume, Dice coefficient (DC), and distance between centers of mass (COMs).

RESULTS: The mean CVSs for T1-, T2-, STIR-, and CT-defined LCs were 3.36, 3.36, 3.79, and 2.50, respectively, implying that LC is mostly visible with the MR STIR sequence. For most cases (12/14), the LC volumes or PTVs from T1, T2, and STIR were smaller than those from CT. The mean reductions of LCs for T1, T2, and STIR from those for CT were 20%, 44%, and 36%, respectively. However, the differences between the volumes of PTV-MRI (the union of three sequences) and PTV-CT were smaller. The DCs between CT- and MRI (union of T1, T2, and STIR)-defined volumes were 0.60 ± 0.15 for LCs and 0.85 ± 0.08 for PTVs. The COM shifts from PTV-MRI to PTV-CT were 0.31 ± 0.25, 0.35 ± 0.39, and 0.36 ± 0.33 cm in the x-, y- and z-axis, respectively. The average PTV-MRI:PTV-CT volume ratio was 1.11±0.22, ranging from 1.00 to 1.25 for most cases (10/14). In 12 of 14 cases, MRI-defined LC included extra regions that would not be visible from CT.

CONCLUSIONS: MRI substantially improves the visibility and accuracy of lumpectomy cavity definition as compared with CT. Although the LC and PTV volumes that are delineated from an individual MRI sequence are generally smaller as compared with those from CT, the volumes, shapes, and locations for the PTV-MRI, defined by the union of T1, T2, and STIR, were comparable with PTV-CT for most of the cases studied. It is feasible to use MRI to replace CT in RT simulations for breast-conserving RT.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content